The expression of CXCR4/CXCL12 determines subsets of patients in systemic lupus erythematosus
- PDF / 74,780 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 120 Downloads / 174 Views
POSTER PRESENTATION
Open Access
The expression of CXCR4/CXCL12 determines subsets of patients in systemic lupus erythematosus Philippe Guilpain1,2,3*, Andrew Wang4, Benjamin F Chong4, Sandrine Chouzenoux2, Loic Guillevin3, Xin J Zhou4, Fangming Lin4, Anna-Marie Fairhurst4, Christopher Boudreaux4, Christian Roux5, Edward K Wakeland4, Laurie Davis4, Frederic Batteux2, Chandra Mohan4 From 6th European Workshop on Immune-Mediated Inflammatory Diseases Nice, France. 23-25 November 2011 Background CXCR4 is a chemokine with numerous effects on the immune system. In murine lupus models, we observed an overexpression of CXCR4, and its ligand, CXCL12, in patients with kidney disease. We assessed whether CXCR4 and CXCL12 were enhanced in human systemic lupus erythematosus (SLE) peripheral blood leukocytes (PBLs) and kidneys. Methods PBLs from 24 consecutive SLE patients were prospectively analyzed by flow cytometry for CXCR4 expression. Human lupus nephritis biopsies (n=16) were immunostained with anti-CXCL12 antibody. Results B cells and CD4+ T cells from SLE patients exhibited an over two-fold increase (p
Data Loading...
